COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluate SAGE-547 in Patients With Essential Tremor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02277106
Recruitment Status : Completed
First Posted : October 28, 2014
Last Update Posted : April 26, 2017
Information provided by (Responsible Party):
Sage Therapeutics

Brief Summary:

Stage 1 is a double-blind, proof-of-concept study designed to evaluate the safety, tolerability, PK, and efficacy of SAGE-547 Injection in male and female patients with essential tremor in the upper limb.

Stage 2 is an open-label arm designed to evaluate the safety, tolerability, PK, and effeciveness of SAGE-547 Injection at a higher dose than in Stage 1. Subjects who completed Stage 1 will be invited to participate in Stage 2.

Condition or disease Intervention/treatment Phase
Essential Tremor Drug: SAGE-547 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor
Study Start Date : September 2014
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tremor

Arm Intervention/treatment
Experimental: SAGE-547
Drug: SAGE-547
Placebo Comparator: Placebo
Intravenous sterile saline
Drug: Placebo

Primary Outcome Measures :
  1. Safety and tolerability of SAGE-547 [ Time Frame: 46 days ]

Secondary Outcome Measures :
  1. Effect of SAGE-547 on patient response as measured by accelerometer (transducer measurement of tremor amplitude) [ Time Frame: 24 hours ]
  2. Effect of SAGE-547 on patient response as measured globally by The Essential Tremor Rating Scale (TETRAS) [ Time Frame: 24 hours ]
  3. Pharmacokinetic (PK) profile of SAGE-547 as measured by AUC, Cmax, Tmax, Css, and Cavg [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, 35-75 years old with a diagnosis of essential tremor with symptoms clearly present in at least 1 upper limb; patient has had tremor present for at least 2 years prior to Screening
  • Off medication, or on a stable dose of medication for their tremor for at least 28 days prior to Screening

Exclusion Criteria:

  • Recent history or active clinically significant manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, eyes, ears, nose, or throat, psychiatric, or neurological (other than essential tremor) disorders
  • Medical history of seizures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02277106

Layout table for location information
United States, Michigan
Sage Study Site
Bingham Farms, Michigan, United States
United States, North Carolina
Sage Study Site
Raleigh, North Carolina, United States
Sponsors and Collaborators
Sage Therapeutics
Layout table for investigator information
Study Chair: Stephen J Kanes, MD, PhD Sage Therapeutics
Additional Information:
Layout table for additonal information
Responsible Party: Sage Therapeutics Identifier: NCT02277106    
Other Study ID Numbers: 547-ETD-201
First Posted: October 28, 2014    Key Record Dates
Last Update Posted: April 26, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Essential Tremor
Neurologic Manifestations
Nervous System Diseases
Movement Disorders
Central Nervous System Diseases